- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00731120
Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Participants in this study will be randomly assigned to receive either 2.5 mg or 10 mg of vortioxetine or a placebo once daily for an eight week treatment period.
Participants will be seen weekly during the first 2 weeks of treatment, and then every 2 weeks up to the end of the 8-week treatment period. Total commitment time is up to 12 weeks.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone
-
-
California
-
Anaheim, California, Stany Zjednoczone
-
Cerritos, California, Stany Zjednoczone
-
Costa Mesa, California, Stany Zjednoczone
-
Orange, California, Stany Zjednoczone
-
Redlands, California, Stany Zjednoczone
-
-
Connecticut
-
Cromwell, Connecticut, Stany Zjednoczone
-
Norwich, Connecticut, Stany Zjednoczone
-
-
Delaware
-
Hockessin, Delaware, Stany Zjednoczone
-
-
Florida
-
Fort Myers, Florida, Stany Zjednoczone
-
Jacksonville, Florida, Stany Zjednoczone
-
Lady Lake, Florida, Stany Zjednoczone
-
Miami, Florida, Stany Zjednoczone
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone
-
Libertyville, Illinois, Stany Zjednoczone
-
-
Indiana
-
Valparaiso, Indiana, Stany Zjednoczone
-
-
Kansas
-
Overland Park, Kansas, Stany Zjednoczone
-
Prairie Village, Kansas, Stany Zjednoczone
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone
-
Braintree, Massachusetts, Stany Zjednoczone
-
Pittsfield, Massachusetts, Stany Zjednoczone
-
-
Missouri
-
St Louis, Missouri, Stany Zjednoczone
-
-
New Jersey
-
Cherry Hill, New Jersey, Stany Zjednoczone
-
-
New York
-
Fresh Meadows, New York, Stany Zjednoczone
-
New York, New York, Stany Zjednoczone
-
Olean, New York, Stany Zjednoczone
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone
-
Columbus, Ohio, Stany Zjednoczone
-
Middleburg Heights, Ohio, Stany Zjednoczone
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone
-
-
Pennsylvania
-
Emmaus, Pennsylvania, Stany Zjednoczone
-
Philadelphia, Pennsylvania, Stany Zjednoczone
-
Reading, Pennsylvania, Stany Zjednoczone
-
-
South Carolina
-
North Charleston, South Carolina, Stany Zjednoczone
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone
-
-
Texas
-
Houston, Texas, Stany Zjednoczone
-
San Antonio, Texas, Stany Zjednoczone
-
-
Virginia
-
Midlothian, Virginia, Stany Zjednoczone
-
-
Wisconsin
-
Waukesha, Wisconsin, Stany Zjednoczone
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Has a primary diagnosis of Generalized Anxiety Disorder according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR®) criteria (classification code 300.02).
- Has a Hamilton Anxiety Scale total score ≥ 20.
- Has a Hamilton Anxiety Scale score ≥ 2 on both item 1 (anxious mood) and item 2 (tension).
- Has a Montgomery-Åsberg Depression Rating Scale total score ≤16.
Exclusion Criteria:
Has 1 or more of the following:
- Any current psychiatric disorder other than Generalized Anxiety Disorder as defined in the DSM-IV-TR (as assessed by the Mini International Neuropsychiatric Interview [MINI]).
- Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
- Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR and participant must have a negative urine drug screen prior to Baseline.
- Presence or history of a clinically significant neurological disorder (including epilepsy).
- Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc.).
- Any Axis II disorder that might compromise the study.
- Is taking excluded medications.
- Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on Item 10 (suicidal thoughts) of the Montgomery-Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.
- Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
- Has received electroconvulsive therapy within 6 months prior to Screening.
- Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
- Has a clinically significant unstable illness.
- Has an alanine aminotransferase, aspartate aminotransferase, or total bilirubin level > 1.5 times the upper limit of normal.
- Has a serum creatinine of > 1.5 × the upper limit of normal.
- Has a previous history of cancer that had been in remission for less than 5 years.
- Has thyroid stimulating hormone value outside the normal range.
- Has an abnormal electrocardiogram.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Komparator placebo: Placebo
Kapsułki odpowiadające placebo wortioksetyny, doustnie, raz dziennie przez okres do 8 tygodni.
|
Kapsułki pasujące do placebo wortioksetyny
|
Eksperymentalny: Vortioxetine 2.5 mg
Vortioxetine 2.5 mg encapsulated tablets, orally, once daily for up to 8 weeks.
|
Kapsułkowane tabletki wortioksetyny o natychmiastowym uwalnianiu
Inne nazwy:
|
Eksperymentalny: Vortioxetine 10 mg
Vortioxetine 10 mg encapsulated tablets, orally, once daily for up to 8 weeks.
|
Kapsułkowane tabletki wortioksetyny o natychmiastowym uwalnianiu
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
Ramy czasowe: Baseline and Week 8
|
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms.
Each symptom is rated from 0 (absent) to 4 (maximum severity).
Total scores range from 0 to 56 where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.
Total scores above 30 are rare, but indicate very severe anxiety.
Least Squares (LS) means were from an analysis of covariance (ANCOVA) model with treatment and center as fixed factors and the Baseline value as a covariate.
|
Baseline and Week 8
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
Ramy czasowe: Baseline and Weeks 1, 2, 4 and 6
|
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms.
Each symptom is rated from 0 (absent) to 4 (maximum severity).
Total scores range from 0 to 56 where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.
Total scores above 30 are rare, but indicate very severe anxiety.
LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
|
Baseline and Weeks 1, 2, 4 and 6
|
Percentage of Responders in HAM-A Total Score at Week 8
Ramy czasowe: Baseline and Week 8
|
Response was defined as a participant with a ≥50% decrease from Baseline in the HAM-A total score.
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms.
Each symptom is rated from 0 (absent) to 4 (maximum severity).
Total scores range from 0 (symptoms absent) to 56 (maximum severity).
|
Baseline and Week 8
|
Percentage of Participants in HAM-A Remission at Week 8
Ramy czasowe: Week 8
|
Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms.
Each symptom is rated from 0 (absent) to 4 (maximum severity).
Total scores range from 0 (symptoms absent) to 56 (maximum severity).
|
Week 8
|
Clinical Global Impression Scale-Global Improvement (CGI-I) at Each Week Assessed
Ramy czasowe: Baseline and Weeks 1, 2, 4, 6 and 8.
|
The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
LS means were from an ANCOVA model adjusting for Baseline CGI-S score, center, and treatment.
|
Baseline and Weeks 1, 2, 4, 6 and 8.
|
Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)
Ramy czasowe: Baseline and Weeks 1, 2, 4, 6 and 8.
|
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis.
Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
LS means were from an ANCOVA model adjusting for Baseline score, center, and treatment.
|
Baseline and Weeks 1, 2, 4, 6 and 8.
|
Change From Baseline in Hospital Anxiety and Depression (HAD) Scales
Ramy czasowe: Baseline and Weeks 1, 4 and 8.
|
The HAD scale is completed by the participant and comprises two subscales, one measuring depression (focusing on the state of lost interest and diminished pleasure response) and one measuring anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks).
Each subscale is made up of 7 items that are assessed on a scale of 0 = no anxiety/depression to 3 = severe feeling of anxiety/depression.
Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days.
Scores for the depression and anxiety subscales are summed separately and not combined, with each score ranging from 0 to 21 (maximal severity).
LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
|
Baseline and Weeks 1, 4 and 8.
|
Change From Baseline in Sheehan Disability Scale (SDS) at Week 8
Ramy czasowe: Baseline and Week 8
|
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities.
The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely).
The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
|
Baseline and Week 8
|
Change From Baseline in 36-item Short-form Health Survey (SF-36)
Ramy czasowe: Baseline and Week 8
|
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile.
The 8 health concepts are: 1. Limitation in physical activities because of health problems.
2. Limitations in usual role activities because of physical health problems.
3. Bodily pain.
4. Limitations in social activities because of physical or emotional problems.
5. General mental health (psychological distress and well-being).
6. Limitations in usual role activities because of emotional problems.
7. Vitality (energy and fatigue).
8. General health perception.
Each scale ranges from 0 (best) - 100 (worst).
LS means were from an ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.
|
Baseline and Week 8
|
Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire
Ramy czasowe: Baseline and Week 8
|
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
|
Baseline and Week 8
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Zaburzenia psychiczne
- Procesy patologiczne
- Choroba
- Zaburzenia lękowe
- Fizjologiczne skutki leków
- Agentów neuroprzekaźników
- Molekularne mechanizmy działania farmakologicznego
- Depresanty ośrodkowego układu nerwowego
- Środki uspokajające
- Leki psychotropowe
- Inhibitory wychwytu serotoniny
- Inhibitory wychwytu neuroprzekaźników
- Modulatory transportu membranowego
- Środki serotoninowe
- Środki przeciwdepresyjne
- Agoniści receptora serotoninowego 5-HT1
- Agoniści receptora serotoninowego
- Antagoniści serotoniny
- Środki przeciwlękowe
- Antagoniści receptora serotoninowego 5-HT3
- Wortioksetyna
Inne numery identyfikacyjne badania
- LuAA21004_309
- U1111-1114-2380 (Identyfikator rejestru: WHO)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Uogólnione zaburzenie lękowe
-
Jagannadha R AvasaralaZakończonyStwardnienie rozsiane | Zapalenie nerwu wzrokowego | Neuromyelitis Optica Spectrum Disorder Atak | Zapalenie nerwu wzrokowego i spektrum zaburzeń nerwu wzrokowego Nawrót | Neuromyelitis Optica Spectrum Disorder ProgresjaStany Zjednoczone
-
Experimental and Clinical Research Center, a cooperation...RekrutacyjnyStwardnienie rozsiane | Choroby demielinizacyjne | Zapalenie nerwu wzrokowego | Neuromyelitis Optica Spectrum Disorder Atak | Choroba związana z przeciwciałami glikoproteinowymi mieliny oligodendrocytówWłochy, Stany Zjednoczone, Argentyna, Australia, Botswana, Brazylia, Kolumbia, Dania, Francja, Niemcy, Indie, Izrael, Japonia, Republika Korei, Hiszpania, Zjednoczone Królestwo, Zambia
Badania kliniczne na Placebo
-
SamA Pharmaceutical Co., LtdNieznanyOstre zapalenie oskrzeli | Ostra infekcja górnych dróg oddechowychRepublika Korei
-
National Institute on Drug Abuse (NIDA)ZakończonyUżywanie konopi indyjskichStany Zjednoczone
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyZakończonyMężczyźni z cukrzycą typu II (T2DM)Niemcy
-
Heptares Therapeutics LimitedZakończonyFarmakokinetyka | Problemy z bezpieczeństwemZjednoczone Królestwo
-
West Penn Allegheny Health SystemZakończonyAstma | Alergiczny nieżyt nosaStany Zjednoczone
-
Soroka University Medical CenterZakończony
-
Regado Biosciences, Inc.ZakończonyZdrowy ochotnikStany Zjednoczone
-
Longeveron Inc.ZakończonyZespół niedorozwoju lewego sercaStany Zjednoczone
-
ItalfarmacoZakończonyDystrofia mięśniowa BeckeraHolandia, Włochy